<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Yd Bio Limited — News on 6ix</title>
<link>https://6ix.com/company/yd-bio-limited</link>
<description>Latest news and press releases for Yd Bio Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/yd-bio-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7979024982d98966ddb4e.webp</url>
<title>Yd Bio Limited</title>
<link>https://6ix.com/company/yd-bio-limited</link>
</image>
<item>
<title>YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-and-eg-biomed-jointly-launch-nationwide-telehealth-platform-to-accelerate-commercialization-of-cancer-detection-and-decentralized-clinical-services-across-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-and-eg-biomed-jointly-launch-nationwide-telehealth-platform-to-accelerate-commercialization-of-cancer-detection-and-decentralized-clinical-services-across-the-united-states</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company’s commercialization of early cancer detection and</description>
</item>
<item>
<title>YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-ceo-dr-ethan-shen-details-strategic-roadmap-for-integrated-oncology-ecosystem</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-ceo-dr-ethan-shen-details-strategic-roadmap-for-integrated-oncology-ecosystem</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-strategic-partnership-with-yc-biotech-co-ltd-to-establish-a-taiwan-us-dual-core-regulatory-platform</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-strategic-partnership-with-yc-biotech-co-ltd-to-establish-a-taiwan-us-dual-core-regulatory-platform</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-enters-into-binding-letter-of-intent-to-acquire-safe-save-medical-cell-sciences-and-technology-co-ltd-bolstering-leadership-in-advanced-immunocell-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-enters-into-binding-letter-of-intent-to-acquire-safe-save-medical-cell-sciences-and-technology-co-ltd-bolstering-leadership-in-advanced-immunocell-therapy</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-enters-into-mou-to-merge-with-eg-biomed-advancing-dna-methylation-driven-ai-platforms-for-cancer-diagnostics-and-drug-development</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-enters-into-mou-to-merge-with-eg-biomed-advancing-dna-methylation-driven-ai-platforms-for-cancer-diagnostics-and-drug-development</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-major-milestones-and-unveils-robust-2026-clinical-and-commercial-roadmap</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-major-milestones-and-unveils-robust-2026-clinical-and-commercial-roadmap</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-expands-us-presence-with-newly-planned-california-facilities-and-operations-center</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-expands-us-presence-with-newly-planned-california-facilities-and-operations-center</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-showcases-its-innovative-diagnostic-and-precision-medicine-portfolios-at-the-9th-healthcare-expo-taiwan</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-showcases-its-innovative-diagnostic-and-precision-medicine-portfolios-at-the-9th-healthcare-expo-taiwan</guid>
<pubDate>Tue, 09 Dec 2025 14:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No. 4F, M1004, where it presented its latest advances in three core portfolios: early cancer det</description>
</item>
<item>
<title>YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-expands-okaidxtm-testing-portfolio-to-pancreatic-and-colorectal-cancer-detection-across-the-us-and-provides-clinical-research-update-on-pancreatic-cancer-early-detection</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-expands-okaidxtm-testing-portfolio-to-pancreatic-and-colorectal-cancer-detection-across-the-us-and-provides-clinical-research-update-on-pancreatic-cancer-early-detection</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-us-ophthalmology-market-entry-advances-across-diagnostics-and-lsc-exosome-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-us-ophthalmology-market-entry-advances-across-diagnostics-and-lsc-exosome-therapeutics</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-and-eg-biomed-expand-us-access-to-okaidxtm-a-cfdnamethylation-blood-test-for-posttreatment-breast-cancer-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-and-eg-biomed-expand-us-access-to-okaidxtm-a-cfdnamethylation-blood-test-for-posttreatment-breast-cancer-monitoring</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc. (“EG BioMed”)’s CLIA/CAP‑certified laboratory in the Un</description>
</item>
<item>
<title>YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-ltd-rings-nasdaq-opening-bell-to-celebrate-listing-under-ticker-ydes</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-ltd-rings-nasdaq-opening-bell-to-celebrate-listing-under-ticker-ydes</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Taipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-business-partner-eg-biomed-achieves-cap-accreditation-advancing-us-clinical-testing-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-business-partner-eg-biomed-achieves-cap-accreditation-advancing-us-clinical-testing-capabilities</guid>
<pubDate>Fri, 10 Oct 2025 12:37:00 GMT</pubDate>
<description>Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. (“EG BioMed”) one of the Company’s licensing partners for pancreatic and breast cancer detection and with 3D Global to develop treatment for eye disorders, has been accredited by the College of American Pathologist</description>
</item>
<item>
<title>YD Bio Limited Reports Unaudited Half Year 2025 Financial Results</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-reports-unaudited-half-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-reports-unaudited-half-year-2025-financial-results</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA</description>
</item>
<item>
<title>YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market</title>
<link>https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-closing-of-business-combination-and-listing-on-the-nasdaq-global-market</link>
<guid isPermaLink="true">https://6ix.com/company/yd-bio-limited/news/yd-bio-limited-announces-closing-of-business-combination-and-listing-on-the-nasdaq-global-market</guid>
<pubDate>Fri, 29 Aug 2025 11:30:00 GMT</pubDate>
<description>YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. ("Breeze"), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols</description>
</item>
</channel>
</rss>